1-Year Follow up to the 1473-IMIQ Study

Completed

• Conditions: Keratosis

• Registration Number: NCT00114023
• Lead Sponsor: Graceway Pharmaceuticals, LLC

Brief Summary

This is a 1-year follow-up study to evaluate the long-term effects in subjects who completely cleared their actinic keratosis (AK) lesions in the 1473-IMIQ study. The 1473-IMIQ study evaluated the safety and effectiveness of imiquimod 5% cream compared to a placebo cream for the treatment of AK.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-01
• Study First Submitted: 2005-06-13
• Study First Submitted QC: 2005-06-13
• Study First Posted: 2005-06-14
• Status Verified: 2006-10
• Last Update Submitted: 2007-02-16
• Last Update Posted: 2007-02-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

• Subject had to participate in the 1473-IMIQ Study AND have had 100% clearance of AK lesions

Exclusion Criteria

• Did not use any topical preparations in the previous treatment area within 24-hours of the scheduled visit.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified